Akonni Biosystems and Seegene have entered into a non-exclusive licensing agreement to develop both point-of-care and ultra-high throughput diagnostic screening assays to simultaneously detect a variety of infectious pathogens known to cause respiratory disease from a single patient sample.
The combination of Seegene’s Dual Priming Oligo (DPO) multiplex PCR technology and Akonni’s TruArray gel-drop microarray technology are expected to reduce the cost of genetic testing.
Seegene said its Dual Priming Oligo (DPO) provides substantial testing accuracy and efficiency in detection of single nucleotide polymorphisms and mutations related to cancer or drug resistance.
TruArray is based on technology first developed at Argonne National Laboratory and the Engelhardt Institute of Molecular Biology, and utilizes gel-drop microarrays specifically optimized for medical applications.
TruArray tests are designed to run on Akonni’s TruDx systems for point of care or its TruSentry system for multiplex genetic testing of up to 3,000 samples per day.